Back to search results

UVA-1 Phototherapy for Scleroderma Hand Tightening

This study is investigating whether UVA-1 Phototherapy can help improve skin tightening and hand function in people with scleroderma. Scleroderma (Systemic sclerosis) is a rare disease that can cause skin to become thick and less flexible. The study will compare the treated hand to the untreated hand after 30 UVA-1 treatments. To join, you must be at least 18 years old, have scleroderma affecting both hands equally, and be able to attend twice-weekly UVA-1 sessions. You also cannot change your other scleroderma medications during the first 100 days of the study. The main goal is to see if there's an improvement in hand function using a score called HAMIS. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design
This is an interventional study with a planned enrollment of 30 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will receive UVA-1 Phototherapy treatments twice weekly for approximately 100 days. They must also be able to attend these sessions.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured after 30 UVA-1 treatments have been completed, which is approximately 100 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04875078

UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma

Enrolling by Invitation
NAAges 18+InterventionalTreatment
University of Utah
~30 participants
Updated 2024-12-18 on ClinicalTrials.gov
What's tested:UVA-1 Phototherapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
HAMIS score of treated hand compared to the HAMIS score of the untreated hand after 30 UVA-1 treatments have been completed.
Measured over Approximately 100 days

Conditions

Scleroderma

Explore related trials

Scleroderma

Where it's being run

1 sites across 1 states
Utah1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be able to understand and provide written informed consent
Scleroderma skin involvement affecting both hands approximately equally
Age of at least 18-years-old
Male or female
Ability to engage in twice weekly UVA1 sessions
No changes in systemic therapy during the first 100 days of the study period

Exclusion

On photosensitizing medication
Inability to complete study visits
UV light therapy in the 4 weeks prior to entering the study
Commercial tanning or excessive sun exposure in the 4 weeks prior to entering the study
Current pregnancy or planned pregnancy during the study period
Use of topical therapies other than emollients (suprapotent corticosteroids) in the 2 weeks prior to entering the study
History of intolerance to ultraviolet light
Any other condition that will disqualify the patient from the study in the opinion of the investigator

What this trial measures

  • HAMIS score of treated hand compared to the HAMIS score of the untreated hand after 30 UVA-1 treatments have been completed.Approximately 100 days

    HAMIS graded on a 0-3 scale, where 0 corresponds to normal function and 3 denotes that the individual is unable to perform the item.